Abstract:[Objective] To evaluate the safety and early clinical efficacy of 3D printed semi-pelvis reconstruction for defect secondary to tumor resection. [Methods] A retrospective study was done on 12 patients who received semi-pelvis reconstruction with 3D printed prostheses for pelvic tumor in our department from January 2022 to April 2023. The documents regarding to perioperative conditions and shortterm follow-up results were evaluated. [Results] All the 12 patients were successfully operated, with an average operation time of (339.3± 97.1) min, intraoperative blood loss of (956.3±708.8) ml, the intraoperative suspended red blood cell infusion of (4.5±3.0) units, and intraoperative plasma infusion of (412.5±359.4) ml. All of them were followed up for (7.2±4.0) months on an average, 1 patient died 7 months after surgery due to tumor progression, and 1 patient suffered dislocation 1 year after surgery and underwent surgical reduction. Compared with those preoperatively, pain VAS score significantly decreased at the last follow-up [(3.3±0.5), (2.0±0.7), P=0.014], whereas the Harris hip score [(46.7±5.4), (64.8±7.3), P=0.003], the MSTS score [(11.0±4.8), (16.3±2.9), P<0.001] significantly increased. [Conclusion] The semipelvis reconstruction with 3D printed prostheses does effectively reduce the pain, and improve the function postoperatively, which is a safe and effective reconstruction method.